O
MGNX icon

OrbiMed’s MacroGenics MGNX Stock Holding History

OrbiMed’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-149,400
Closed -$4.03M – 148
2016
Q2 		$4.03M Sell
149,400
-167,600
-53% -$3.78M 0.04% 113
2016
Q1 		$5.94M Hold
317,000
– – 0.06% 110
2015
Q4 		$9.82M Hold
317,000
– – 0.09% 92
2015
Q3 		$6.79M Hold
317,000
– – 0.07% 104
2015
Q2 		$12M Buy
+317,000
New +$10.4M 0.1% 100
2014
Q2 		– Sell
-491,897
Closed -$13.7M – 141
2014
Q1 		$13.7M Hold
491,897
– – 0.17% 73
2013
Q4 		$13.5M Buy
+491,897
New +$12.9M 0.2% 73

Other funds holding MGNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

OrbiMed's MGNX Position: Q3 2016 in Review

OrbiMed sold out of MacroGenics (MGNX) in Q3 2016, closing a stake of 149,400 shares — an estimated $4.03M sold.

OrbiMed first reported a position in MGNX in Q4 2013 and held it in 7 quarters. The position peaked at $13.7M in Q1 2014. 132 funds tracked by Wall St. Rank hold MGNX as of Q3 2016.

  • OrbiMed reported no remaining MacroGenics position as of Q3 2016 after selling out during the quarter.
  • OrbiMed sold 149,400 MacroGenics shares in Q3 2016, an estimated $4.03M.
  • OrbiMed first reported a position in MacroGenics in Q4 2013 and held it in 7 quarters.
  • OrbiMed's MacroGenics position peaked at $13.7M in Q1 2014.
  • 132 funds tracked by Wall St. Rank held MacroGenics as of Q3 2016.

Based on OrbiMed's 13F filing for Q3 2016, filed 14 Nov 2016.